| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8727365 | Gastroenterology | 2017 | 65 Pages |
Abstract
In an analysis of serum samples from more than 500 patients with IBD, we observed a negative correlation between serum levels of tryptophan and disease activity. Increased levels of tryptophan metabolites-especially of quinolinic acid-indicated a high activity of tryptophan degradation in patients with active IBD. Tryptophan deficiency could contribute to development of IBD or aggravate disease activity. Interventional clinical studies are needed to determine whether modification of intestinal tryptophan pathways affects the severity of IBD.
Keywords
QUIAHRTNFIDOCDAICAITDOTrpCARD9HBIPICIBDAUCamino acidPicolinic acidQuinolinic acidinflammationinterferonIFNinterleukinindoleamine 2,3-dioxygenaseinflammatory bowel diseasesCrohn’s diseaseTryptophanTryptophan 2,3-dioxygenaseKYNDietCrohn’s Disease Activity IndexAnti-inflammatorytumor necrosis factorarea under the curveNADnicotinamide adenine dinucleotideC-reactive proteinCRPUlcerative colitiskynureninearyl hydrocarbon receptor
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Susanna Nikolaus, Berenice Schulte, Natalie Al-Massad, Florian Thieme, Dominik M. Schulte, Johannes Bethge, Ateequr Rehman, Florian Tran, Konrad Aden, Robert Häsler, Natalie Moll, Gregor Schütze, Markus J. Schwarz, Georg H. Waetzig, Philip Rosenstiel,